Signia Therapeutics to present preclinical results at the 6th ISIRV-AVG Antiviral Conference

November 09, 2018

Signia Therapeutics announces it has been invited to present company and update of development at the upcoming 6th ISIRV-AVG “Advances in Respiratory Virus Therapeutics”.

Presentation will be delivered by Dr. Andrés Pizzorno, cofounder of Signia Therapeutics and Project Manager, as invited speaker, on Tuesday November 13th at 9.30 am. Dr. Pizzorno will be presenting an overview of Signia Therapeutics’ innovative drug discovery platform as well as an update on preclinical data of its leading repurposed anti-influenza drug candidate, currently undergoing Phase 2b clinical evaluation.

The conference, organized by the Antiviral Group (AVG) of the International Society for Influenza and Other Respiratory Virus Diseases (ISIRV), will be held at the Hilton Washington DC/Rockville Hotel between November 13-15th. The conference represents an excellent opportunity for the productive exchange between members of the industry and academia to discuss the most significant advances in the prevention and treatment of viral respiratory infections. Visit the ISIRV-AVG website ( for detailed information. 

Leave a comment

Signia - Copyright 2021. All right reserved.